Zobrazeno 1 - 10
of 136
pro vyhledávání: ''
Autor:
Thomas Tsitsias, Tom Routledge, John Pilling, Lukacs Veres, Lawrence Okiror, Juliet King, Karen Harrison-Phipps, Andrea Bille
Publikováno v:
Lung Cancer. 151:84-90
Objective to validate the proposed N descriptor revision on a large cohort of patients and assess the impact of tumour location on the distribution pattern of lymph node metastases for patients with NSCLC. Methods This is a retrospective review of a
Autor:
Simon Ekman, Fred R. Hirsch, Johan Botling, Johanna Sofia Margareta Mattsson, Linnea LaFleur, Georgios Tsakonas, Teresa Boyle, Christopher J. Rivard, Patrick Micke
Publikováno v:
Lung Cancer. 133:69-74
Background c-MET protein overexpression has been proposed as a biomarker in non-small cell lung cancer (NSCLC), albeit its role in the clinical setting has not been firmly established yet. Patients and methods: We designed a retrospective cohort stud
Autor:
Xu-Chao Zhang, Ben-Yuan Jiang, Lin-Lin Li, Kai Yin, Mei-Mei Zheng, Yang-Si Li, Xue-Ning Yang, Qing Zhou, Hong-Hong Yan, Wen-Zhao Zhong, Wen-Feng Li, Yi-Long Wu, Jin-Ji Yang, Hai-Yan Tu, Hua-Jun Chen
Publikováno v:
Lung Cancer. 131:134-138
Leptomeningeal metastases (LM) had increased in advanced non-small-cell lung cancer (NSCLC) over the last 10 years. The survival outcome remained overall poor, heterogeneous and was reported in association with genotypes in lung cancer patients with
Autor:
Wendy A Cooper, Stephen Clarke, Tamkin Ahmadzada, Candice Clarke, Glen Reid, Brian C. McCaughan, Anthony Linton, Rebecca Asher, Kenneth Lee, Steven Kao
Publikováno v:
Lung Cancer. 130:35-41
A number of key immune regulators show prognostic value in malignant pleural mesothelioma (MPM), but the association between Bridging integrator 1 (BIN1), indoleamine 2,3 dioxygenase 1 (IDO1) and patient outcome has not been investigated. We aimed to
Autor:
Xiaojuan Zhang, Xuanxuan Zheng, Jinpo Yang, Peng Li, M. Zhang, Xiangtao Yan, Zhiyong Ma, Huijuan Wang, Guowei Zhang
Publikováno v:
Lung Cancer. 128:6-12
Objective: The objective of this study was to investigate whether first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy improves the prognosis of patients with advanced non-sm
Autor:
Yongsheng Zhang, Yangyang Liu, Chang Chen, Xie Qiu, Shanzhou Duan, Feng Li, Donglai Chen, Yiting Zhou, Yongbing Chen
Publikováno v:
Lung Cancer. 124:211-218
To characterize the relationship between metastasis-associated protein 1 (MTA1) and spread through air spaces (STAS), and to investigate the joint prognostic value of MTA1 and STAS in resected lung adenocarcinomas.We retrospectively reviewed 208 oper
Autor:
Torben Riis Rasmussen, Susanne Oksbjerg Dalton, Anders Løkke, Jane Christensen, Niels Lyhne Christensen
Publikováno v:
Christensen, N L, Løkke, A, Dalton, S O & Rasmussen, T R 2018, ' Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients ', Lung Cancer, vol. 124, pp. 40-44 . https://doi.org/10.1016/j.lungcan.2018.07.025
Introduction In addition to the highest incidence rate of lung cancer among the Nordic countries, Denmark has the highest mortality rate. Moreover, rates of tobacco and alcohol consumption are among the highest in these countries. Method In a populat
Autor:
Yasushi Goto, Yuichiro Ohe, Hidehito Horinouchi, Noriko Motoi, Shintaro Kanda, Yutaka Fujiwara, Katsutoshi Sekine, Noboru Yamamoto
Publikováno v:
Lung Cancer. 124:179-188
Objectives Nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has been shown to yield a durable response and significant prolongation of the survival in some patients with non-small-cell lung cancer (NSCLC). However, ident
Autor:
Carlos Alvarez, Ana Belén Enguita, Julio Sánchez de Cos, Roldán Cortés, Luis Seijo, Cristina Balcells, Eduard Monsó, Esther Barreiro, Marta Cascante, Anabel Martinez-Romero, Ramon Rami-Porta, Laura Millares
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
instname
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients diagnosed in early stage and surgically-treated have five-year mortality rate >20%. The identification of biomarkers able to predict progression and death may help to identify patients needing
Autor:
Steven Shema, Jessica Beck, Teruhide Ishigame, Curtis C. Harris, Ana I. Robles, Delphine Lissa, Rintaro Noro, Elise D. Bowman, Valery Bliskovsky, Marguerite J. Tucker
Publikováno v:
Lung Cancer. 122:151-159
OBJECTIVES: Surgery with curative intent is the standard treatment for stage I lung adenocarcinoma. However, disease recurrence occurs in a third of patients. Prognostic biomarkers are needed to improve postoperative management. Here, we evaluate the